Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Cancer Immunol Res. 2021 Feb 22;9(5):583–597. doi: 10.1158/2326-6066.CIR-20-0427

Figure 4. Antigen engagement maintains CD49b and further upregulates CD49a.

Figure 4.

Thy1.1+ OT-I Nur77-GFP splenocytes were transferred into C57BL/6 mice, which were subsequently immunized with OVA, polyIC, and anti-CD40. CD49b SP Thy1.1+ OT-I effectors were isolated and transferred into B16-F1 or B16-OVA tumor-bearing or tumor-free mice as in Figure 2A. Tumors and spleens were harvested 1 or 7 days post-transfer (PT). (A) The number of Thy1.1+ CD3+ CD8+ cells were quantitated, and (B) Nur77-GFP expression and (C-E) CD49b and CD49a expression was evaluated by flow cytometry. n=6–10 mice/group, 2 independent experiments. Groups were compared using Welch’s corrected T-tests. Bar graphs and error bars indicate mean +/− SD. Factors of significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.